{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T22:26:17Z","timestamp":1775687177621,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,3,1]],"date-time":"2026-03-01T00:00:00Z","timestamp":1772323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1016\/j.pharma.2026.03.002","type":"journal-article","created":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T17:04:06Z","timestamp":1774371846000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Analyses de cycle de vie des m\u00e9dicaments \u00e0 l\u2019h\u00f4pital\u00a0: faisabilit\u00e9 et perspectives d\u2019int\u00e9gration, application \u00e0 l\u2019adalimumab"],"prefix":"10.1016","author":[{"given":"Virginie","family":"Siorat","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marion","family":"Tano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Olivier","family":"Parent de Curzon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascal","family":"Paubel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Albane","family":"Degrassat-Th\u00e9as","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharma.2026.03.002_bib0090","series-title":"D\u00e9carboner la sant\u00e9 pour soigner durablement","year":"2023"},{"key":"10.1016\/j.pharma.2026.03.002_bib0095","series-title":"Accompagnement dans l\u2019\u00e9laboration de l\u2019empreinte carbone des entreprises du m\u00e9dicament","year":"2022"},{"key":"10.1016\/j.pharma.2026.03.002_bib0100","series-title":"D\u00e9carbonons les industries du m\u00e9dicament\u00a0\u2013\u00a0Rapport final","year":"2025"},{"key":"10.1016\/j.pharma.2026.03.002_bib0105","series-title":"Zoom sur l\u2019\u00e9coprescription","year":"2024"},{"key":"10.1016\/j.pharma.2026.03.002_bib0110","series-title":"Service\/Produits pharmaceutiques, Base empreinte","year":"2018"},{"key":"10.1016\/j.pharma.2026.03.002_bib0115","series-title":"M\u00e9thodologie d\u2019\u00e9valuation de l\u2019empreinte carbone des m\u00e9dicaments","year":"2025"},{"key":"10.1016\/j.pharma.2026.03.002_bib0120","series-title":"Note d\u2019information no\u00a0DGOS\/CABINET\/DGCS\/PNRR\/2025\/153\u00a0du 29\u00a0octobre 2025\u00a0relative aux modalit\u00e9s de mise en \u0153uvre de la m\u00e9thodologie publique d\u2019empreinte carbone des m\u00e9dicaments","author":"Direction g\u00e9n\u00e9rale de la coh\u00e9sion sociale (DGCS)","year":"2025"},{"key":"10.1016\/j.pharma.2026.03.002_bib0125","unstructured":"Agence nationale de s\u00e9curit\u00e9 du m\u00e9dicament et des produits de sant\u00e9 (ANSM). R\u00e9pertoire des Sp\u00e9cialit\u00e9s Pharmaceutiques. [En ligne\u00a0: https:\/\/agence-prd.ansm.sante.fr\/php\/ecodex\/index.php (consult\u00e9 le 21\/04\/2025)]."},{"key":"10.1016\/j.pharma.2026.03.002_bib0130","unstructured":"The European Medicines Agency (EMA). Medicines authorised for human use. [En ligne\u00a0: https:\/\/www.ema.europa.eu\/en\/medicines (consult\u00e9 le 21\/04\/2025)]."},{"key":"10.1016\/j.pharma.2026.03.002_bib0135","unstructured":"The U.S. Food and Drug Administration (FDA). FDA-Approved Drugs. [En ligne\u00a0: https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm (consult\u00e9 le 21\/04\/2025)]."},{"key":"10.1016\/j.pharma.2026.03.002_bib0140","unstructured":"EcoTransIT World. [En ligne\u00a0: https:\/\/www.ecotransit.org\/fr\/ (consult\u00e9 le 22\/05\/2025)]."},{"key":"10.1016\/j.pharma.2026.03.002_bib0145","unstructured":"Searoutes. [En ligne\u00a0: https:\/\/searoutes.com\/ (consult\u00e9 le 22\/05\/2025)]."},{"key":"10.1016\/j.pharma.2026.03.002_bib0150","unstructured":"GoogleMaps. [En ligne\u00a0: https:\/\/www.google.com\/maps (consult\u00e9 le 22\/05\/2025)]."},{"key":"10.1016\/j.pharma.2026.03.002_bib0155","unstructured":"ChatGPT. [En ligne\u00a0: https:\/\/chatgpt.com\/ (consult\u00e9 le 21\/08\/2025)]."},{"issue":"Suppl. 1","key":"10.1016\/j.pharma.2026.03.002_bib0160","doi-asserted-by":"crossref","first-page":"A305","DOI":"10.1016\/j.rhum.2024.10.198","article-title":"Quelle est l\u2019empreinte carbone de l\u2019adalimumab d\u2019origine et de ses diff\u00e9rents m\u00e9dicaments biosimilaires\u00a0?","volume":"91","author":"Moninot","year":"2024","journal-title":"Rev Rhum"},{"key":"10.1016\/j.pharma.2026.03.002_bib0165","unstructured":"NovoNordisk. FlexPen\u00ae incl. API and needle\u00a0\u2013\u00a0product carbon footprint. [En ligne\u00a0: https:\/\/www.novonordisk.com\/content\/dam\/nncorp\/global\/en\/sustainable-business\/pdfs\/esg-portal\/lca\/product-carbon-footprint-flexpen.pdf (consult\u00e9 le 22\/05\/2025)]."},{"key":"10.1016\/j.pharma.2026.03.002_bib0085","unstructured":"Eckelman M, Litan R. Life Cycle Assessment of the Prefilled ApiJect Injector. [En ligne\u00a0: https:\/\/apiject.com\/wp-content\/uploads\/2024\/10\/ApiJect-Environmental-Study-Report-FINAL.pdf (consult\u00e9 le 22\/05\/2025)]."}],"container-title":["Annales Pharmaceutiques Fran\u00e7aises"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450926000404?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003450926000404?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T21:37:05Z","timestamp":1775684225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003450926000404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3]]},"references-count":17,"alternative-id":["S0003450926000404"],"URL":"https:\/\/doi.org\/10.1016\/j.pharma.2026.03.002","relation":{},"ISSN":["0003-4509"],"issn-type":[{"value":"0003-4509","type":"print"}],"subject":[],"published":{"date-parts":[[2026,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Analyses de cycle de vie des m\u00e9dicaments \u00e0 l\u2019h\u00f4pital\u00a0: faisabilit\u00e9 et perspectives d\u2019int\u00e9gration, application \u00e0 l\u2019adalimumab","name":"articletitle","label":"Article Title"},{"value":"Annales Pharmaceutiques Fran\u00e7aises","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharma.2026.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Acad\u00e9mie Nationale de Pharmacie. Published by Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}